Moleculin Biotech, Inc. (MBRX) closed the most recent trading day at $1.07, making no change from the previous trading session.

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that since the May 1st, 2020 temporary suspension by the Securities and Exchange Commission (SEC) of trading in the securities of Moleculin Biotech, Inc. (MBRX), additional information has come to the Company's attention regarding claims disseminated by third parties.

NEW YORK, May 18, 2020 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that the trading halt status in Moleculin Biotech Inc. (Nasdaq: MBRX) was changed to "additional.

Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Moleculin Biotech, Inc. ("Moleculin" or the "Company") (NASDAQ: MBRX). Investors who purchased Moleculin securities may be affected.

VANCOUVER, British Columbia, April 29, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to.

JP Morgan Private Bank Head of Cross-Asset Thematic Strategy Anastasia Amoroso joins Yahoo Finance’s Seana Smith to discuss the latest market action as more states move to reopen their economies in the wake of the coronavirus.

Professor of Medicine at Yale and Director of The Yale New Haven Hospital Center for Outcomes Research and Evaluation Dr. Harlan Krumholz joins Yahoo Finance’s Seana Smith to discuss Moderna’s recent headway in an early-stage coronavirus vaccine trial.

The Securities and Exchange Commission temporarily halted trading in three more stocks on Monday because of questions regarding the accuracy of information in the marketplace about a drug candidate for the coronavirus illness COVID-19.

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced securities of the Company have been placed in a temporary trading halt following notification by the US Securities and Exchange Commission.

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chief Executive Officer, will participate on the COVID-19 panel at Maxim Group's Infectious Disease Virtual Conference on May 5th from 3:45 p.m. ET to 5:00 p.m. ET. To RSVP for the virtual conference, please click through: Maxim Group's Infectious Disease Virtual Conference.

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration ("FDA") has granted the Company's request for a Pre-IND Meeting to provide guidance regarding the Company's plan to study its drug candidate, WP1122, in a clinical trial for patients with COVID-19 (the disease caused by the SARS-CoV-2 coronavirus). In addition, Moleculin provided a general update on its WP1122 development efforts.

Since early February, the U.S. Securities and Exchange Commission has issued a series of warnings to investors to beware of companies hawking miracle cures to the disease known as COVID-19. Surely everyone -- the SEC included -- is certainly eager to see a cure to the disease, which has claimed more than 257,000 lives, found.Still, there's an old adage that warns us that "if something sounds too good to be true, it probably is."So far, the SEC has felt compelled to halt trading in the shares of no fewer than 29 separate publicly-traded companies that are suspected of having made false or misleading statements about the efficacy of cures they're supposedly working on.The latest entries onto this ignominious list: CNS Pharmaceuticals (CNSP), Moleculin Biotech (MBRX), and WPD Pharmaceuticals (WCOTF) -- three unprofitable, revenue-less, sub-$100 million market capitalization microcaps trading for penny-stock (below $5) prices.As reported Tuesday, the SEC halted trading in the shares of all three companies Monday, saying it has "questions regarding the accuracy and adequacy of information in the marketplace about the company and its securities." Specifically, all three companies are apparently involved in working up a drug candidate labeled WP1122, which is being touted as a cure to COVID-19.In an April 13 CNS press release, CNS describes WP1122 as a "prodrug" that, once ingested and metabolized by a patient, will produce in vivo something called 2-deoxy-D-glucose, or "2-DG." Supposedly, 2-DG has been shown in independent research conducted at the University of Frankfurt, Germany (and have you ever noticed how miracle drugs always seem to be verified effective somewhere too far away to conveniently check?) to "reduce replication of the coronavirus by 100% in in vitro testing," reports Marketwatch. (By the way, the "research" has not been peer-reviewed).In a statement, CNS CEO John Climaco stood by "the accuracy and adequacy of information the company has released into the marketplace regarding the company and its product candidates."Be that as it may, perhaps you are wondering how three separate companies came to be involved in developing one and the same, hitherto unheard of coronavirus cure -- even one as miraculous as WP1122 -- in the first place? Well, the story goes like this:Once upon a time, Moleculin Biotech developed a portfolio of drug candidates that might (or might not) be good for something or other. At some point, WPD licensed the rights to develop these drugs, and at some other point, CNS wandered into the picture and signed an agreement to help WPD with that development, promising to pay WPD about $1 million to move WP1122 through a successful Phase 2 study, in return for WPD's promise to share in 50% of any eventual net sales of the drug once it passes that Phase, passes Phase 3 as well, and is eventually approved for sale on the market.Thus was this tangled web weaved.Now, thanks to the SEC, it appears that the jig is up. It only remains to be seen whether shareholders in the three companies will cry "foul" -- or thank the regulators for protecting investors from misinformation, and the pie-in-the-sky promises of penny stocks.In reaction, Maxim analyst Jason McCarthy noted, "Effective immediately, Maxim Group is temporarily suspending coverage of Moleculin Biotech, Inc. (MBRX) and removing the rating and price target due to the Order of Suspension of Trading of MBRX shares issued by the Securities and Exchange Commission (SEC) on May 1, 2020."To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it is now authorized by the Polish Department of Registration of Medicinal Products known as URPL to accelerate the Phase 1 dose escalation portion of its clinical trial of Annamycin for the treatment of acute myeloid leukemia (AML).

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has received notification from Nasdaq that trading in the Company's common stock will resume on Thursday, May 28, 2020.

NEW YORK, May 27, 2020 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading in Moleculin Biotech, Inc. (Nasdaq: MBRX) is scheduled to resume on Thursday, May 28,.

Is (MBRX) Outperforming Other Medical Stocks This Year?

Moleculin Biotech Inc. and CNS Pharmaceuticals Inc. said Monday their shares remain halted on Nasdaq with the exchange seeking additional information from each company. Shares werehalted temporarily on May 1 by the Securities and Exchange Commission in a halt that was meant to expire at 11.59 p.m. on May 15. The halt came because of questions regarding the accuracy of information in the marketplace about a drug candidate for the coronavirus illness COVID-19, the SEC said. Moleculin's stock was halted along with CNS and WPD Pharmaceuticals Inc. , because of questions relating to a drug candidate called WP1122. CNS was working with WPD to develop the drug; WPD had previously licensed rights to a portfolio of drug candidates including WP1122 from Moleculin Biotech for certain regions.

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its intention to adjourn its 2020 Annual Meeting of Stockholders.

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that pending the receipt of additional information from the Company, Nasdaq has halted the trading in the Company's common stock. The Company is actively working with the staff of Nasdaq to provide it with all requested information, and hopes to begin trading as soon as possible.

Moleculin Biotech Inc. and CNS Pharmaceuticals Inc. said Monday they did not solicit or have any advance knowledge about claims made by third parties about drug candidate WP1122 and its effect on COVID-19. The two Houston-based companies had their stocks temporarily halted by the Securities and Exchange Commission on May 1 over claims and information in the marketplace about WP1122, along with the stock of WPD Pharmaceuticals Inc. of Vancouver, British Columbia. WPD had previously licensed rights to a portfolio of drug candidates including WP1122 from Moleculin Biotech for certain regions, while CNS is working with WPD on development. In separate statements, the companies said those parties made claims and distributed information about WP1122 during the period stretching from March 20 and May 5 regarding the potential efficacy of the drug in dealing with the coronavirus that causes COVID-19. "The company neither solicited, had advance knowledge of, nor played any role in the preparation of such information, claims or statements," Moleculin said in a statement. "Moleculin encourages all investors and persons of interest to look at the Company's releases and filings regarding the potential development of WP1122 for the treatment of COVID-19." CNS used the same language in its release. The SEC halt is scheduled to end on May 15.